Infinium PharmachemNSE:INFINIUM -2.10%87 Interest Coverage is 7.76 as of Mar. 2026, which is 45% above its 10-year median of 5.35. GuruFocus rates NSE:INFINIUM with a GF Score™ of 87/100 and a GF Value™ of ₹304.24 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,232 Chemicals companies, Infinium Pharmachem ranks worse than 59.25% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Infinium Pharmachem's
Operating Income
for the
six
months ended in Mar. 2026 was ₹96 Mil. Infinium Pharmachem's Interest Expense for the
six
months ended in Mar. 2026 was ₹-12 Mil.
Infinium Pharmachem's interest coverage for the quarter that ended in Mar. 2026 was 7.76.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Infinium Pharmachem's Interest Coverage or its related term are showing as below:
NSE:INFINIUM'
s Interest Coverage Range Over the Past 10 Years
Min: 2.09 Med: 5.35 Max: 8.46
Current: 6.61
NSE:INFINIUM's Interest Coverage is ranked worse than 59.25% of 1232
companies
in the Chemicals industry
Industry Median: 10.18
vs NSE:INFINIUM: 6.61
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Infinium Pharmachem Interest Coverage Related Terms
Infinium Pharmachem Interest Coverage Historical Data
* Premium members only.
The historical data trend for Infinium Pharmachem's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Chemicals subindustry, Infinium Pharmachem's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infinium Pharmachem Interest Coverage vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Infinium Pharmachem's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Infinium Pharmachem's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infinium Pharmachem (NSE:INFINIUM) has a Interest Coverage of 7.76 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Infinium Pharmachem and its competitors. This is 45% above median its historical median of 5.35. Over the past decade, Infinium Pharmachem's Interest Coverage has ranged from 2.09 to 8.46. According to the industry distribution chart, Infinium Pharmachem ranks #730 out of 1232 companies in the Chemicals industry, placing it in the top 59.3%.
Is Infinium Pharmachem's Interest Coverage too high?
Infinium Pharmachem's current Interest Coverage of 7.76 is 45% above median its 10-year median of 5.35. Over the past 10 years, this metric has ranged from a low of 2.09 to a high of 8.46. The Chemicals industry median Interest Coverage is 10.18. Infinium Pharmachem's value of 7.76 is 23.8% below this industry median. Based on the distribution chart, Infinium Pharmachem ranks #730 out of 1232 companies in the Chemicals industry, which is below the industry midpoint. Overall, Infinium Pharmachem has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Infinium Pharmachem's Interest Coverage compare to DOW?
According to the Chemicals industry distribution chart, Infinium Pharmachem ranks #730 out of 1232 companies for Interest Coverage. This places Infinium Pharmachem in the lower half of its industry. The industry median Interest Coverage is 10.18. Infinium Pharmachem's value of 7.76 is 23.8% below this benchmark. Historically, Infinium Pharmachem's own Interest Coverage has ranged from 2.09 to 8.46 over the past decade. While the company's 10-year median is 5.35 vs. the industry median of 10.18, Infinium Pharmachem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Chemicals company?
The median Interest Coverage among Chemicals companies is 10.18, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Infinium Pharmachem's current Interest Coverage of 7.76 is 23.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Infinium Pharmachem and its competitors. For the Chemicals industry, the median Interest Coverage is 10.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infinium Pharmachem's current Interest Coverage is 7.76, which is 45% above median its own 10-year median of 5.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinium Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Infinium Pharmachem (NSE:INFINIUM) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹304.24, compared to a current price of ₹211.90 — trading 30.4% below its estimated fair value. The current Interest Coverage is 7.76, which is 45% above median its 10-year median of 5.35 and 23.8% below the Chemicals industry median of 10.18. Infinium Pharmachem's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Infinium Pharmachem (NSE:INFINIUM), the current Interest Coverage is 7.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Infinium Pharmachem (NSE:INFINIUM) Overvalued in 2026?
Based on GuruFocus' analysis, Infinium Pharmachem stock appears to be undervalued.
The current stock price of ₹211.90 is trading 30.4% below its estimated GF Value™ of ₹304.24.
GuruFocus considers Infinium Pharmachem to be Significantly Undervalued.
Key valuation signals for NSE:INFINIUM:
Interest Coverage: 7.76 (45% above median its 10-year median of 5.35)
GF Value™: ₹304.24 vs. price of ₹211.90 (30.4% below fair value)
Industry Position: 23.8% below the Chemicals median (#730 of 1232)
No single metric tells the full story. See the NSE:INFINIUM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Infinium Pharmachem Ltd is engaged in the business of manufacturing and supplying Iodine, Iodine Derivatives and Active Pharmaceutical Ingredients (APIs). It provides fully integrated customized services from R & D to Commercial scale manufacturing and packaging for its products to the Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals and various other chemicals Industries.
87GF Score
Get the complete analysis for NSE:INFINIUM
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFINIUM has been successfully added to your 
